Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Vividion Therapeutics extended its chemoproteomics platform reach with a Roche collaboration worth up to $1.5 billion in milestones, layered atop existing…
Bayer has agreed to pay up to $2 billion to acquire Vividion Therapeutics, a San Diego-based biotech using chemoproteomics to attack undruggable targets in…
Global oncology medicine spending reached $186 billion in 2021, up 12% versus 2020, while global immunology spending reached approximately $115 billion. The…
Source summaries from our enrichment pipeline; follow links for originals.
All 17 sources with sentiment breakdown →
Bayer agreed to acquire San Diego-based Vividion for $1.5B upfront plus up to $500M in milestone payments (~$2B total). Vividion's chemoproteomics platform targets historically undruggable proteins including cancer- and inflammation-related transcription factors. Closed August 19, 2021. Post-close update (as of June 2026): Vividion has operated as an independent, wholly-owned Bayer subsidiary and the platform thesis is materially validated - it has advanced multiple chemoproteomics-derived programs into the clinic, including a Phase I oral STAT3 inhibitor (VVD-130850, dosing started Feb 2024), a Phase I oral RAS-PI3Ka inhibitor (VVD-159642 / NCT06804824, first patient dosed Apr 2025), and in June 2025 secured exclusive worldwide rights to clinical-stage covalent WRN inhibitor VVD-214 (RO7589831) from its 2020 Roche collaboration.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bayer AG / Vividion Therapeutics, Inc. (this deal) | 2021 | $2.0B | — |
| Bayer AG / Schering AG | 2006 | $21.5B | 79 |
| Bayer AG / BlueRock Therapeutics | 2002 | $600M | 79 |
| Bayer AG / Merck & Co., Inc. | 2014 | $14.2B | 71 |
| Bayer AG / Schering AG (residual squeeze-out) | 2007 | $985M | 69 |
| Bayer AG / Arvinas, Inc. | 2019 | $1.0B | 59 |
| Bayer AG / Merck & Co. Inc. | 2014 | $14.2B | 56 |
← Browse all deals · How we score deals
More: 2021 deals · Bayer AG deals · Immunology deals